Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies
- PMID: 22465037
- DOI: 10.1016/j.yjmcc.2012.03.006
Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies
Abstract
The utility of anthracycline antineoplastic agents in the clinic is compromised by the risk of cardiotoxicity. It has been calculated that approximately 10% of patients treated with doxorubicin or its derivatives will develop cardiac complications up to 10 years after the cessation of chemotherapy. Oxidative stress has been established as the primary cause of cardiotoxicity. However, interventions reducing oxidative stress have not been successful at reducing the incidence of cardiotoxicity in patients treated with doxorubicin. New insights into the cardiomyocyte response to oxidative stress demonstrate that underlying differences between in vitro and in vivo toxicities may modulate the response to superoxide radicals and related compounds. This has led to potentially new uses for pre-existing drugs and new avenues of exploration to find better pharmacotherapies and interventions for the prevention of cardiotoxicity. However, much work still must be done to validate the clinical utility of these new approaches and proposed mechanisms. In this review, the authors have reviewed the molecular mechanisms of the pathogenesis of acute and chronic doxorubicin-induced cardiotoxicity and propose potential pharmacological interventions and treatment options to prevent or reverse this specific type of heart failure.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Similar articles
-
Pathogenesis and prevention of doxorubicin cardiomyopathy.Tsitologiia. 1997;39(10):928-37. Tsitologiia. 1997. PMID: 9505340 Review.
-
Role of iron in anthracycline cardiotoxicity: new tunes for an old song?FASEB J. 1999 Feb;13(2):199-212. FASEB J. 1999. PMID: 9973309 Review.
-
Anthracycline-induced cardiotoxicity: clinical course, risk factors, pathogenesis, detection and prevention--review of the literature.Med Sci Monit. 2000 Mar-Apr;6(2):411-20. Med Sci Monit. 2000. PMID: 11208348 Review.
-
Adriamycin-induced myocardial toxicity: new solutions for an old problem?Int J Cardiol. 2007 Apr 12;117(1):6-15. doi: 10.1016/j.ijcard.2006.05.005. Epub 2006 Jul 24. Int J Cardiol. 2007. PMID: 16863672 Review.
-
Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4.J Pharm Pharmacol. 2004 Jun;56(6):757-68. doi: 10.1211/0022357023565. J Pharm Pharmacol. 2004. PMID: 15231041
Cited by
-
Peptide Szeto‑Schiller 31 ameliorates doxorubicin‑induced cardiotoxicity by inhibiting the activation of the p38 MAPK signaling pathway.Int J Mol Med. 2021 Apr;47(4):63. doi: 10.3892/ijmm.2021.4896. Epub 2021 Mar 2. Int J Mol Med. 2021. PMID: 33649779 Free PMC article.
-
Doxorubicin cardiomyopathy is ameliorated by acacetin via Sirt1-mediated activation of AMPK/Nrf2 signal molecules.J Cell Mol Med. 2020 Oct;24(20):12141-12153. doi: 10.1111/jcmm.15859. Epub 2020 Sep 11. J Cell Mol Med. 2020. PMID: 32918384 Free PMC article.
-
S100A8 and S100A9 Are Associated with Doxorubicin-Induced Cardiotoxicity in the Heart of Diabetic Mice.Front Physiol. 2016 Aug 5;7:334. doi: 10.3389/fphys.2016.00334. eCollection 2016. Front Physiol. 2016. PMID: 27547188 Free PMC article.
-
Synergistic impacts of Montelukast and Klotho against doxorubicin-induced cardiac toxicity in Rats.Toxicol Res (Camb). 2022 Jun 20;11(4):592-604. doi: 10.1093/toxres/tfac023. eCollection 2022 Aug. Toxicol Res (Camb). 2022. PMID: 36051669 Free PMC article.
-
The Association of Mitochondrial Copy Number With Sarcopenia in Adult Survivors of Childhood Cancer.J Natl Cancer Inst. 2021 Nov 2;113(11):1570-1580. doi: 10.1093/jnci/djab084. J Natl Cancer Inst. 2021. PMID: 33871611 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
